> Detailanzeige

Bobin, Arthur; Fouquet, Guillemette; Duhamel, Alain; Manier, Salomon; Karlin, Lionel; Kolb, Brigitte; Tiab, Mourad; Araujo, Carla; Meuleman, Nathalie; Malfuson, Jean-Valère; Bourquard, Pascal; Lenain, Pascal; Jaccard, Arnaud; Belhadj, Karim; Attal, Michel; Moreau, Philippe; Avet-Loiseau, Herve; Hulin, Cyrille; Facon, Thierry; Leleu, Xavier

Maintenance with weekly carfilzomib in elderly newly diagnosed multiple myeloma (IFM 2012-03)

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Maintenance with weekly carfilzomib in elderly newly diagnosed multiple myeloma (IFM 2012-03)
  • Beteiligte: Bobin, Arthur; Fouquet, Guillemette; Duhamel, Alain; Manier, Salomon; Karlin, Lionel; Kolb, Brigitte; Tiab, Mourad; Araujo, Carla; Meuleman, Nathalie; Malfuson, Jean-Valère; Bourquard, Pascal; Lenain, Pascal; Jaccard, Arnaud; Belhadj, Karim; Attal, Michel; Moreau, Philippe; Avet-Loiseau, Herve; Hulin, Cyrille; Facon, Thierry; Leleu, Xavier
  • Erschienen: American Society of Clinical Oncology (ASCO), 2019
  • Erschienen in: Journal of Clinical Oncology, 37 (2019) 15_suppl, Seite 8029-8029
  • Sprache: Englisch
  • DOI: 10.1200/jco.2019.37.15_suppl.8029
  • ISSN: 0732-183X; 1527-7755
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: 8029 Background: Prolonged treatments have significantly improved survival in newly diagnosed multiple myeloma (NDMM). Lenalidomide (IMiDs), is currently approved in this indication, but remains a daily treatment, although oral, and may favor side effects in the long run. Furthermore, the use of a proteasome inhibitor (PI) is warranted in certain type of MM, such as high-risk. Carfilzomib, a second generation PI, has proved active combined with an acceptable security profile but its added benefit when given continuously is unknown. We thought to study maintenance Carfilzomib for elderly NDMM (eNDMM). Methods: The IFM 2012-03 multicenter phase I KMP (Carfilzomib, Melphalan, Prednisone) weekly study for eNDMM (≥ 65 years old) determined the maximal tolerated dose of weekly Carfilzomib at 70mg/m². We focus herein on the second part of the study with IV Carfilzomib monotherapy given at 36mg/m² for 13 cycles maintenance on an every 2 weeks schedule. Results: Thirty eNDMM were recruited in IFM 2012-03. Median age is 75, with 56% R-ISS 2 or 3 and 11% high-risk cytogenetic. With K weekly from 36 to 70mg/m², OS is reported at 93.3%, including 46.7% ≥CR; median PFS is 35.8 months and median OS was not reached. Twenty-two (73%) patients started K maintenance and 16 (73%) completed it. Four patients progressed and 2 stopped for AEs (renal amylosis, sensory neuropahty) during the maintenance phase. At maintenance completion, 50% were ≥CR. From the start of maintenance, in landmark analysis, median PFS is 28.1 months and the estimated 36-months OS approximately 70%. Conclusions: Carfilzomib monotherapy can be used safely in maintenance for 1 year in eNDMM, including for patients above 75 years. K maintenance may lead to deep response rate, certainly a most relevant prognostic factor for prolonged survival. Therefore, Carfilzomib maintenance, characterized with a simple administration modality, might be considered as an alternative to Lenalidomide and integrate the armamentarium of prolonged therapy in eNDMM. Clinical trial information: NCT02302495.
  • Zugangsstatus: Freier Zugang